Ainos Inc (AIMD)

$0.63 -0.02 (-3.77%)
Market Cap 9.16M
Revenue (ttm) 120,000.00
Net Income (ttm) -13.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11,475.00%
Debt to Equity Ratio 0.08
Volume 218,200
Avg Vol 673,466
Day's Range N/A - N/A
Shares Out 14.09M
Stochastic %K 22%
Beta 1.41
Analysts Strong Buy
Price Target N/A

Latest News on AIMD

Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

Jan 17, 2025, 9:00 AM EST - 17 hours ago

Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

Jan 13, 2025, 10:00 AM EST - 4 days ago

Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

Dec 18, 2024, 12:05 PM EST - 4 weeks ago

CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

Dec 18, 2024, 8:00 AM EST - 4 weeks ago

Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement

Dec 13, 2024, 8:00 AM EST - 5 weeks ago

Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement

Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing

Dec 4, 2024, 8:00 AM EST - 6 weeks ago

Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing

Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug

Dec 2, 2024, 8:00 AM EST - 6 weeks ago

Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug

Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments

Nov 13, 2024, 8:00 AM EST - 2 months ago

Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments

Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

Nov 11, 2024, 8:00 AM EST - 2 months ago

Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities

Nov 8, 2024, 8:00 AM EST - 2 months ago

Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities

Ainos Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:30 PM EST - 2 months ago

Ainos Reports Third Quarter 2024 Financial Results

Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets

Oct 28, 2024, 8:00 AM EDT - 2 months ago

Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets

Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast

Oct 24, 2024, 10:50 AM EDT - 3 months ago

Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast

Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Oct 7, 2024, 8:00 AM EDT - 3 months ago

Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA

Sep 25, 2024, 8:00 AM EDT - 4 months ago

Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA

Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome

Sep 24, 2024, 10:55 AM EDT - 4 months ago

Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome

Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options

Sep 23, 2024, 8:00 AM EDT - 4 months ago

Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options

Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts

Sep 20, 2024, 8:00 AM EDT - 4 months ago

Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts

Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Sep 17, 2024, 8:00 AM EDT - 4 months ago

Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention

Sep 3, 2024, 8:30 AM EDT - 4 months ago

Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention

Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:30 AM EDT - 5 months ago

Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter

Aug 26, 2024, 8:30 AM EDT - 5 months ago

Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter

Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Aug 19, 2024, 9:15 AM EDT - 5 months ago

Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024

Aug 12, 2024, 8:00 AM EDT - 5 months ago

Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024

Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing

Aug 9, 2024, 4:15 PM EDT - 5 months ago

Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing

Ainos Concludes Growth Financing From Lind Partners

Aug 6, 2024, 7:30 AM EDT - 5 months ago

Ainos Concludes Growth Financing From Lind Partners

Ainos Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:15 PM EDT - 5 months ago

Ainos Reports Second Quarter 2024 Financial Results

Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

Jul 23, 2024, 8:30 AM EDT - 6 months ago

Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Jun 14, 2024, 8:00 AM EDT - 7 months ago

Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

May 15, 2024, 8:00 AM EDT - 8 months ago

Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

Ainos Reports First Quarter 2024 Financial Results

May 13, 2024, 4:10 PM EDT - 8 months ago

Ainos Reports First Quarter 2024 Financial Results

Ainos Raises $9 Million in Growth Capital with Existing Shareholder

May 7, 2024, 8:00 AM EDT - 9 months ago

Ainos Raises $9 Million in Growth Capital with Existing Shareholder

Ainos Reports Full Year 2023 Financial Results

Mar 8, 2024, 4:20 PM EST - 11 months ago

Ainos Reports Full Year 2023 Financial Results

Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms

Feb 5, 2024, 9:00 AM EST - 1 year ago

Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms

Ainos Announces $1.75 Million Follow-On Funding

Jan 24, 2024, 9:00 AM EST - 1 year ago

Ainos Announces $1.75 Million Follow-On Funding

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 2, 2024, 9:00 AM EST - 1 year ago

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell

Dec 26, 2023, 9:00 AM EST - 1 year ago

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell

Ainos, Inc. Announces Stock Consolidation

Dec 12, 2023, 8:00 AM EST - 1 year ago

Ainos, Inc. Announces Stock Consolidation

Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical

Nov 28, 2023, 8:30 AM EST - 1 year ago

Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical

Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Nov 21, 2023, 8:30 AM EST - 1 year ago

Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:30 PM EST - 1 year ago

Ainos Reports Third Quarter 2023 Financial Results

Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA

Nov 6, 2023, 8:00 AM EST - 1 year ago

Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA

Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement

Sep 25, 2023, 8:30 AM EDT - 1 year ago

Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement

With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients

Sep 19, 2023, 12:26 PM EDT - 1 year ago

With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients

Ainos' VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients

Sep 18, 2023, 7:00 AM EDT - 1 year ago

Ainos' VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients

Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan

Sep 5, 2023, 7:00 AM EDT - 1 year ago

Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan

Ainos, Inc - The AI Nose "Knows" What's Inside Your Body and Beyond

Aug 15, 2023, 1:29 PM EDT - 1 year ago

Ainos, Inc - The AI Nose "Knows" What's Inside Your Body and Beyond

Ainos Reports Second Quarter 2023 Financial Results

Aug 11, 2023, 4:30 PM EDT - 1 year ago

Ainos Reports Second Quarter 2023 Financial Results

Ainos Celebrates First Listing Anniversary on Nasdaq

Aug 10, 2023, 8:00 AM EDT - 1 year ago

Ainos Celebrates First Listing Anniversary on Nasdaq

Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption

Aug 9, 2023, 8:00 AM EDT - 1 year ago

Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption